Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement

Tumor, Brain

Intracranial Pressure Increase

Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors

Non-invasive measurement of intracranial pressure

Kantonsspital Aarau

non_invasive_aICP_Tumor

Non-Invasive Measurement of Absolute Intracranial Pressure in Patients With Mass Effective Brain Tumors

The primary outcome is the non-invasive, absolute intracranial pressure (aICP) before brain tumor surgery, as determined by the "NON-INVASIVE ICP ABSOLUTE VALUE METER" in mmHG.

The secondary outcome is to demonstrate correlation between increased aICP and clinical and radiological signs.

Javier Fandino, MD

Hydrops Saccular

Service Imagerie 1

Scleral Hydrops and Intralabyrinthine Schwannoma

To measure saccule size (membranous labyrinth structure) in patients with intralabyrinthine schwannoma on a high resolution fluid sequence (FIESTA-C) in 3T MRI

University Hospital, Strasbourg, France

Vestibular Schwannoma

Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI

Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI

A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.

Radiation Necrosis

Route of administration:
In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.

25% Mannitol

Route of administration:
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.

Low-dose Intra-arterial Bevacizumab

University of Kentucky Medical Center

Norton Brownsboro Hospital

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Imaging response to therapy will be quantitatively assessed on MRI using volumetric analysis. Regions of T2 and FLAIR prolongation above contralateral white matter will be calculated and quantified in cubic centimeters. Region of interest (ROI) will be created using a semi-automated, thresholding and region-growing technique. Enhancement of the lesion will be calculated using similar volumetric ROI analysis with a contrast threshold of 40% above background and measured in cubic centimeters.

To assess the utility of intra-arterial bevacizumab treatment in allowing decreased steroid usage, the quantity of steroid use (measured as mg of decadron per day) will be documented.

Quantitative improvement in headache will be assessed by performing the Headache Impact Test (HIT-6), which is a fixed-length 6-item questionnaire. The score for this questionnaire can range from 36 to 78, with higher scores indicating worse headache burden.

We will determine how severely headache affect the patient's life before and after treatment by performing the MIDAS 5-item questionnaire: Score of 0 to 5 signifies little or no disability, score of 6 to 10, signifies mild disability, score of 11 to 20 signifies moderate disability, and score of 21+ signifies severe disability.

In order to investigate the immediate and post-operative neurocognitive sequelae of intra-arterial bevacizumab, patients who consent to a formal neuropsychological battery will be tested. Subtests from the NAB (Neuropsychological Assessment Battery, Stern & White, PAR Inc.) have been chosen for brevity, sensitivity, and due to the wide range of available normative data (ages 18-97). In addition, the Wechsler Test of Adult Reading (WTAR, Pearson Inc.) will be administered to provide an estimate of premorbid cognitive functioning.

Safety of intra-arterial bevacizumab will be assessed by noting the number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Objective improvement in neurological exam will be assessed by performing serial neurological exams.

Quantitative improvement in functional status will be assessed by performing Karnofsky Performance Status Scale (KPS). The KPS score can range from 0 to 100.

Quantitative improvement in quality of life will be assessed by performing CDC HRQOL-14 "Healthy Days Measure." This survey contains 14 items to measure health-related quality of life. It consists of three modules: the 4-item Healthy Days Core Module (CDC HDQOL-4), 5-item Activity Limitations Module, and 5-item Healthy Days Symptom Module. The items in this survey are either subjective and require yes/no answer, or they involve the number of days during the past 30 days that the patient had problems secondary to different physical or mental health issues.

Cost analysis of a single treatment of low dose intra-arterial bevacizumab after osmotic blood-brain-barrier disruption as compared to conventional intravenous bevacizumab use for radiation necrosis (7.5 mg/kg IV-Bevacizumab every 3 weeks for 4 cycles)

Shervin Dashti, MD

Principal Investigator

Norton Healthcare

University of Kentucky

Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.

Meniere Disease

plasma vasopressin, V2 receptor, cyclic AMP

vasopressin, V2 receptor and cyclic AMP

Meniere's disease group at Department of ORL, Osaka University, School of Medicine

Department of Otolaryngology, Osaka University, School of Medicine

Vasopressin and V2 Receptor in Meniere's Disease

Meniere's disease association at Osaka University

Osaka University

Osaka City University

Facial Palsy

methylprednisolone administrated intra and post operatively

neurilemmoma/edema

non_invasive_aICP_Tumor

Scleral Hydrops and Intralabyrinthine Schwannoma

Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Vasopressin and V2 Receptor in Meniere's Disease

Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery

科学支持的最完整的草药数据库